Browsing: trials

Rare paediatric central nervous system (CNS) tumours comprise a biologically-heterogeneous group of low-incidence diseases that present significant challenges to both therapeutic development and clinical research, limiting the availability of high-quality evidence to guide clinical care. The UK3CR Children’s Cancer Research Group (CRG) CNS Tumours Subgroup convened a multidisciplinary workshop to identify research priorities and establish…

Women remain underrepresented in authorship and leadership roles of clinical trials of structural heart disease (SHD), and targeted efforts and policies to diversify trial leadership may help address the downstream inequities in the generation of cardiovascular evidence, according to a systematic review and meta-analysis published Aug. 12 in JACC: Advances

New information has been revealed about an advanced manufacturing trial conducted by Australian Army soldiers during Exercise Black Prince 3 in South Australia

Researchers developing a new weight loss drug are looking for people to take part in clinical trials in Bradford

Earlier this year, the U.S. Department of Health and Human Services (HHS) stopped recommending that all children get an annual influenza vaccine. Instead, it made the shot a matter of “shared clinical decision-making”—something for parents and a doctor to weigh case by case—citing, among other reasons, a lack of randomized controlled trials proving the vaccine’s…

Trust me, I know it’s easy to become cynical about industry conferences. After all, there are plenty of opportunities to listen to keynote presentations, network in hotel hallways, and collect enough business cards to last until next year’s event

Eli Lilly (LLY, Financials), a pharmaceutical firm that focuses on diabetes, obesity and other chronic diseases, said it aims to petition for regulatory approval of retatrutide in the first quarter of 2027 after the medicine succeeded in two more phase 3 trials

A new study suggests that the harder a clinical trial works to be flexible and realistic, the more its conclusion leans on statistical assumptions

“Obtaining regulatory approval is one part of the challenge for rare disease therapies. Following approval, HTA agencies and payers evaluate the clinical, economic, and patient-centered value of a therapy to inform pricing, reimbursement, and patient access decisions. Historically, rare disease trials have often relied on small patient populations, single-arm or open-label designs, surrogate endpoints, and…

A stress-mitigation product called BIG BEAN tested its specialized soybean nutrition that may reduce stress-related yield losses